Journey Medical Corporation (NASDAQ:DERM – Free Report) – Equities researchers at HC Wainwright cut their Q3 2026 EPS estimates for Journey Medical in a research note issued to investors on Monday, October 26th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of ($0.08) per share for the quarter, down from their prior forecast of $0.01. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Journey Medical’s current full-year earnings is ($0.02) per share. HC Wainwright also issued estimates for Journey Medical’s Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at $0.15 EPS, FY2028 earnings at $0.45 EPS, FY2029 earnings at $0.66 EPS and FY2030 earnings at $0.72 EPS.
Journey Medical (NASDAQ:DERM – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.01. The business had revenue of $18.51 million for the quarter, compared to analyst estimates of $18.36 million.
Several other research firms have also weighed in on DERM. B. Riley Financial reiterated a “buy” rating and issued a $15.00 price objective (up from $12.00) on shares of Journey Medical in a research note on Thursday, August 13th. Wall Street Zen downgraded Journey Medical from a “buy” rating to a “hold” rating in a research report on Saturday, October 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Journey Medical in a research note on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $14.00.
Check Out Our Latest Stock Report on Journey Medical
Journey Medical Stock Performance
Shares of DERM opened at $4.96 on Wednesday. Journey Medical has a 12 month low of $4.31 and a 12 month high of $9.56. The company has a 50-day moving average price of $6.62 and a two-hundred day moving average price of $6.70.
Hedge Funds Weigh In On Journey Medical
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wasatch Advisors LP grew its stake in Journey Medical by 34.0% during the second quarter. Wasatch Advisors LP now owns 2,858,930 shares of the company’s stock worth $20,241,000 after buying an additional 725,560 shares during the last quarter. Punch & Associates Investment Management Inc. acquired a new position in shares of Journey Medical in the 2nd quarter worth approximately $3,795,000. J. Goldman & Co LP acquired a new position in shares of Journey Medical in the 2nd quarter worth approximately $974,000. BlackRock Inc. bought a new stake in Journey Medical during the 2nd quarter worth approximately $715,000. Finally, Walleye Capital LLC bought a new stake in Journey Medical during the 2nd quarter worth approximately $463,000. 7.25% of the stock is currently owned by institutional investors and hedge funds.
Journey Medical Company Profile
Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and commercializing prescription products for medical dermatology. The company targets conditions that affect the skin, hair and nails, with an emphasis on products that address significant patient needs and can be marketed through its specialty sales organization.
Its portfolio includes Qbrexza (glycopyrronium) cloth, a topical treatment for primary axillary hyperhidrosis, and Targadox (doxycycline hyclate) delayed-release capsules, which are used to treat moderate-to-severe inflammatory acne vulgaris.
Featured Articles
- Five stocks we like better than Journey Medical
- Hidden in Plain Sight: 2 Earnings Winners Investors May Have Missed
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
Receive News & Ratings for Journey Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Journey Medical and related companies with MarketBeat.com's FREE daily email newsletter.
